無料プレビュー

Moderna, Inc. (MRNA) · NASDAQ Global Select

プロフィール

Moderna is a pioneer in mRNA medicine development with a platform technology enabling vaccine and therapeutic candidates across infectious disease, oncology, and rare disease. The company commercializes three products—Spikevax and mNEXSPIKE COVID vaccines and mRESVIA RSV vaccine—and operates a pipeline of 35 therapeutic and vaccine programs in clinical development. Moderna manufactures mRNA medicines through internal facilities in the United States and internationally, supported by contract manufacturers, and maintains strategic collaborations with companies including Merck and Vertex.

主要指標

株価: $197.51 (+0.52%)
時価総額: 784億ドル
PER（今期予想）: -23.7
PBR: 11.6
配当利回り: —
52週レンジ: $22.28 – $212.22
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: S&P 500 0.10%

比較会社: PFE Pfizer Inc.、VRTX Vertex Pharmaceuticals Incorporated、GSK GSK plc、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-05 · 更新: 2026-10-08